- Home
- MGLD vs AKTX Comparison
MGLD vs AKTX Comparison
Compare MGLD & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGLD
- AKTX
- Stock Information
- Founded
- MGLD 1996
- AKTX N/A
- Country
- MGLD United States
- AKTX United States
- Employees
- MGLD N/A
- AKTX N/A
- Industry
- MGLD Finance/Investors Services
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- MGLD Finance
- AKTX Health Care
- Exchange
- MGLD Nasdaq
- AKTX Nasdaq
- Market Cap
- MGLD 37.9M
- AKTX 35.7M
- IPO Year
- MGLD N/A
- AKTX N/A
- Fundamental
- Price
- MGLD $0.82
- AKTX $1.01
- Analyst Decision
- MGLD
- AKTX Strong Buy
- Analyst Count
- MGLD 0
- AKTX 1
- Target Price
- MGLD N/A
- AKTX $5.00
- AVG Volume (30 Days)
- MGLD 8.7K
- AKTX 25.1K
- Earning Date
- MGLD 09-17-2025
- AKTX 08-18-2025
- Dividend Yield
- MGLD N/A
- AKTX N/A
- EPS Growth
- MGLD N/A
- AKTX N/A
- EPS
- MGLD N/A
- AKTX N/A
- Revenue
- MGLD $31,205,000.00
- AKTX N/A
- Revenue This Year
- MGLD N/A
- AKTX N/A
- Revenue Next Year
- MGLD N/A
- AKTX N/A
- P/E Ratio
- MGLD N/A
- AKTX N/A
- Revenue Growth
- MGLD N/A
- AKTX N/A
- 52 Week Low
- MGLD $0.70
- AKTX $0.85
- 52 Week High
- MGLD $2.10
- AKTX $4.22
- Technical
- Relative Strength Index (RSI)
- MGLD 45.83
- AKTX 33.43
- Support Level
- MGLD $0.83
- AKTX $1.01
- Resistance Level
- MGLD $0.90
- AKTX $1.15
- Average True Range (ATR)
- MGLD 0.07
- AKTX 0.04
- MACD
- MGLD -0.00
- AKTX -0.01
- Stochastic Oscillator
- MGLD 16.40
- AKTX 6.60
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.